AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal BehÃ§et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrÃ¶m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.

Overall MarketRank^™

2.89 out of 5 stars

Medical Sector

1st out of 2,043 stocks

Pharmaceutical Preparations Industry

1st out of 771 stocks

2.4 Analyst's Opinion

Consensus Rating
AbbVie has received a consensus rating of Buy. The company's average rating score is 2.76, and is based on 14 buy ratings, 2 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $117.13, AbbVie has a forecasted upside of 1.2% from its current price of $115.78.
Amount of Analyst Coverage
AbbVie has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.9 Community Rank

Outperform Votes
AbbVie has received 1,224 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
AbbVie has received 852 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
AbbVie has received 58.96% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote “Outperform” if you believe ABBV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ABBV will underperform the S&P 500 over the long term. You may vote once every thirty days.

5.0 Dividend Strength

Dividend Leadership
AbbVie is a leading dividend payer. It pays a dividend yield of 4.57%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
AbbVie has been increasing its dividend for 49 years.
Dividend Coverage
The dividend payout ratio of AbbVie is 58.17%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, AbbVie will have a dividend payout ratio of 42.73% next year. This indicates that AbbVie will be able to sustain or increase its dividend.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AbbVie insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $21,981,948.00 in company stock.
Percentage Held by Insiders
Only 0.09% of the stock of AbbVie is held by insiders.
Percentage Held by Institutions
67.49% of the stock of AbbVie is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5 Earnings and Valuation

Earnings Growth
Earnings for AbbVie are expected to grow by 16.13% in the coming year, from $10.48 to $12.17 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AbbVie is 24.48, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.89.
Price to Earnings Ratio vs. Sector
The P/E ratio of AbbVie is 24.48, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 43.74.
Price to Earnings Growth Ratio
AbbVie has a PEG Ratio of 1.54. PEG Ratios above 1 indicate that a company could be overvalued.

See Top Rated MarketRank™ Stocks Here

AbbVie (NYSE:ABBV) Frequently Asked Questions

Is AbbVie a buy right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 2 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AbbVie stock.
View analyst ratings for AbbVie or view top-rated stocks.

What stocks does MarketBeat like better than AbbVie?

Wall Street analysts have given AbbVie a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AbbVie wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is AbbVie's next earnings date?

AbbVie is scheduled to release its next quarterly earnings announcement on Friday, July 30th 2021.
View our earnings forecast for AbbVie.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) posted its quarterly earnings data on Thursday, April, 29th. The company reported $2.95 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $2.83 by $0.12. The business earned $13.01 billion during the quarter, compared to analysts' expectations of $12.84 billion. AbbVie had a trailing twelve-month return on equity of 439.24% and a net margin of 18.16%. The firm's revenue for the quarter was up 50.9% compared to the same quarter last year. During the same quarter last year, the business posted $2.42 EPS.
View AbbVie's earnings history.

How has AbbVie's stock been impacted by Coronavirus?

AbbVie's stock was trading at $84.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ABBV stock has increased by 36.5% and is now trading at $115.78.
View which stocks have been most impacted by COVID-19.

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie declared a quarterly dividend on Thursday, February 18th. Shareholders of record on Thursday, April 15th will be given a dividend of $1.30 per share on Friday, May 14th. This represents a $5.20 dividend on an annualized basis and a yield of 4.49%. The ex-dividend date is Wednesday, April 14th.
View AbbVie's dividend history.

Is AbbVie a good dividend stock?

AbbVie pays an annual dividend of $5.20 per share and currently has a dividend yield of 4.57%. ABBV has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. AbbVie has been increasing its dividend for 49 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of AbbVie is 58.17%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AbbVie will have a dividend payout ratio of 42.73% next year. This indicates that AbbVie will be able to sustain or increase its dividend.
View AbbVie's dividend history.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie updated its second quarter 2021 earnings guidance on Friday, April, 30th. The company provided EPS guidance of 3.050-3.090 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.060. The company issued revenue guidance of $13.60 billion-$13.60 billion, compared to the consensus revenue estimate of $13.52 billion.

What price target have analysts set for ABBV?

17 analysts have issued 12 month price targets for AbbVie's stock. Their forecasts range from $95.00 to $144.00. On average, they anticipate AbbVie's stock price to reach $117.13 in the next twelve months. This suggests a possible upside of 1.2% from the stock's current price.
View analysts' price targets for AbbVie or view top-rated stocks among Wall Street analysts.

Who are AbbVie's key executives?

AbbVie's management team includes the following people:

Mr. Richard A. Gonzalez, Chairman & CEO (Age 67, Pay $7.36M) (LinkedIn Profile)
Dr. Michael E. Severino, Vice Chairman & Pres (Age 55, Pay $4.29M) (LinkedIn Profile)
Mr. Robert A. Michael, Exec. VP & CFO (Age 51, Pay $3.22M) (LinkedIn Profile)
Ms. Laura J. Schumacher, Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec. (Age 58, Pay $4.2M) (LinkedIn Profile)
Dr. Azita Saleki-Gerhardt, Exec. VP of Operations (Age 58) (LinkedIn Profile)
Dr. Thomas J. Hudson, Sr. VP of R&D and Chief Scientific Officer (Age 59)
Ms. Elizabeth Shea, VP of Investor Relations
Mr. Timothy J. Richmond, Exec. VP & Chief HR Officer (Age 55) (LinkedIn Profile)
Mr. Scott C. Brun M.D., VP of Scientific Affairs & Head of AbbVie Ventures
Mr. Henry O. Gosebruch, Exec. VP & Chief Strategy Officer (Age 48) (LinkedIn Profile)

What is Richard A. Gonzalez's approval rating as AbbVie's CEO?

580 employees have rated AbbVie CEO Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among AbbVie's employees.

Who are some of AbbVie's key competitors?

Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN) and Endo International (ENDP).
View all of ABBV's competitors.

What other stocks do shareholders of AbbVie own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), AT&T (T), Bristol-Myers Squibb (BMY), Wheaton Precious Metals (WPM), Rogers Communications (RCI) and Open Text (OTEX).

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

Who are AbbVie's major shareholders?

AbbVie's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.43%), LSV Asset Management (0.18%), Envestnet Asset Management Inc. (0.16%), DekaBank Deutsche Girozentrale (0.14%), The Manufacturers Life Insurance Company (0.14%) and New York State Teachers Retirement System (0.13%). Company insiders that own AbbVie stock include Brian L Durkin, Carlos Alban, Carrie C Strom, Edward J Rapp, Elaine K Sorg, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Richard A Gonzalez, Roxanne S Austin, Timothy J Richmond and William J Chase.
View institutional ownership trends for AbbVie.

Which institutional investors are selling AbbVie stock?

ABBV stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Robeco Institutional Asset Management B.V., Ferguson Wellman Capital Management Inc., LSV Asset Management, Retirement Systems of Alabama, CHURCHILL MANAGEMENT Corp, New York State Teachers Retirement System, and Artemis Investment Management LLP. Company insiders that have sold AbbVie company stock in the last year include Carlos Alban, Carrie C Strom, Elaine K Sorg, Jeffrey Ryan Stewart, Richard A Gonzalez, and Timothy J Richmond.
View insider buying and selling activity for AbbVie or view top insider-selling stocks.

Which institutional investors are buying AbbVie stock?

ABBV stock was bought by a variety of institutional investors in the last quarter, including Diamond Hill Capital Management Inc., Clarus Group Inc., Envestnet Asset Management Inc., Zurcher Kantonalbank Zurich Cantonalbank , GSB Wealth Management LLC, Wedge Capital Management L L P NC, DekaBank Deutsche Girozentrale, and DnB Asset Management AS. Company insiders that have bought AbbVie stock in the last two years include Brian L Durkin, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin, and William J Chase.
View insider buying and selling activity for AbbVie or or view top insider-buying stocks.

How do I buy shares of AbbVie?

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $115.78.

How much money does AbbVie make?

AbbVie has a market capitalization of $204.33 billion and generates $33.27 billion in revenue each year. The company earns $7.88 billion in net income (profit) each year or $8.94 on an earnings per share basis.

How many employees does AbbVie have?

AbbVie employs 47,000 workers across the globe.

Does AbbVie have any subsidiaries?

The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska družba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacéuticos S.A. de C.V., AbbVie Farmacêutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S.à r.l., AbbVie Investments Limited, AbbVie Investments S.à r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementär GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. Ltd., AbbVie Overseas S.à r.l., AbbVie Oy, AbbVie Participações Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. z o.o., AbbVie Productos Farmacéuticos Limitada, AbbVie Products LLC, AbbVie Promoção L.da, AbbVie Pte. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S.à r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Bhd., AbbVie Sp. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tıbbi İlaçlar Sanayi ve Ticaret Limited Şirketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundación AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC.

When was AbbVie founded?

AbbVie was founded in 2013.

What is AbbVie's official website?

The official website for AbbVie is www.abbvie.com.

Where are AbbVie's headquarters?

AbbVie is headquartered at 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.

This page was last updated on 5/5/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

AbbVie Stock Forecast, Price & News

Adding

Adding

Adding AbbVie Inc.

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links

Headlines

About AbbVie

MarketRank™

Overall MarketRank™